Hydroxytyrosol (HT) is a phenolic olive oil chemical that contains antioxidant properties, which means it can neutralise’free radicals’ which cause damage to proteins, lipids and DNA in cells, otherwise known as’oxidative stress’.
In Parkinson’s Disease cell versions, HT has been shown to protect dopaminergic neurons against cell death following oxidative stress and protect against alpha synuclein fibril formation and aggregation from the PC12 cell line.
However, HT independently is rapidly metabolised and has limited ability to make it to the brain. This has previously restricted the potential of HT as a possible treatment for neurological conditions for example Parkinson’s.
Nanocarriers have been found to improve the effectiveness, stability, bioavailability, and the passing across biological membranes of incorporated compounds. Researchers have previously used Pluronic F68 (P68) + dequalinium (DQA) nanocarriers to deliver antioxidants into mitochondria to protect against Parkinson’s Disease.
A new study by the Centre for Nutraceuticals, University of Westminster, today demonstrates that using nanocarriers to produce this olive oil infusion improves its capacity to access the brain at a Parkinson’s-connected cell version.
The analysis used a co-culture system to mimic the brain such as the adrenal barrier that prevents the utilization of toxins, and nerves which are the cells which are damaged in Parkinson’s.
Using nanocarriers can shield HT from being broken down and because of their small dimensions and neutral charge, enable passage across the blood-brain barrier. The researchers showed that these nanocarriers could also enhance the protective effects of HT by up to 12%.
The nanocarriers used in this research were targeted to a specific portion of the cell, the mitochondria, in which the energy is created, since mitochondria are also the main site of oxidative stress. This delivery method has also been shown for a promising mechanism to provide different antioxidants such as curcumin and N-acetylcysteine in comparable versions.
The investigators say additional afield investigation is warranted to evaluate whether the improved neuroprotection using these nanocarriers is shown in more comprehensive models of neurodegeneration.
Mursaleen, L.; Noble, B.; Somavarapu, S.; Zariwala, M.G.
“Micellar Nanocarriers of Hy